Skip to content
Inciteful Med

Standard of Care: Surgery, Radiation, and Observation

Last updated:

Treatment for a non-functioning pituitary adenoma depends on its size and symptoms. Small, asymptomatic tumors are usually monitored. Tumors causing vision loss or hormone issues often require endoscopic transsphenoidal surgery. Radiation is generally reserved for residual tumor growth.

Key Takeaways

  • • Small, asymptomatic non-functioning pituitary adenomas are often monitored with active surveillance instead of immediate treatment.
  • • Endoscopic transsphenoidal surgery, performed through the nose, is the standard method for removing tumors that cause vision or hormone problems.
  • • Complete tumor removal may not be possible if it has invaded the cavernous sinus, which results in a subtotal resection.
  • • Radiation therapy is rarely the first line of treatment but is highly effective at stopping residual tumor fragments from growing after surgery.
  • • Medical therapy, such as the drug Cabergoline, is sometimes used to help stabilize a tumor remnant and prevent it from growing.

When you are diagnosed with a non-functioning pituitary adenoma (NFPA), the treatment plan is rarely “one size fits all.” Because these tumors are benign and slow-growing, the goal is not just to remove the tumor, but to protect your vision and hormone health while minimizing the risks of treatment [1][2].

The Three Paths of Treatment

Standard care typically follows one of three routes depending on the tumor’s size and whether it is causing symptoms [3].

1. Active Surveillance (“Watchful Waiting”)

This is often the first-line choice for incidentalomas (tumors found by accident) that are small (usually microadenomas <10mm) and are not pressing on the optic nerves or causing hormone loss [4][3].

  • What it involves: Periodic MRIs and vision tests to ensure the tumor isn’t growing [5].
  • When to switch to surgery: If the tumor grows significantly or if you begin to lose peripheral vision [6].

2. Surgery (Transsphenoidal)

Surgery is the primary treatment if the tumor is causing vision loss, severe headaches, or significant hormone deficiencies [7][8]. Most modern surgeries are endoscopic transsphenoidal (ETSS).

  • How it works: This is not open skull surgery. The surgeon navigates tiny instruments and a camera through your nasal passages to reach the tumor [9]. Research shows that this endoscopic approach allows for better visualization, leading to higher rates of complete removal (Gross Total Resection) and lower rates of complications compared to older microscopic methods [10][11].
  • The “Knosp” Factor: If your tumor has invaded the cavernous sinus (High Knosp Grade), it may be impossible to remove it all safely. In these cases, the surgeon performs a Subtotal Resection (STR), leaving a small piece behind to avoid damaging major blood vessels or nerves [12][13].
  • Common Surgical Side Effects: Recovery usually takes a few weeks. Some patients may experience transient complications like a leak of the cerebrospinal fluid (CSF leak) from the nose or temporary excessive thirst and urination known as diabetes insipidus [14]. These are usually manageable but important to discuss with your surgeon.

3. Radiation Therapy

Radiation is rarely the first treatment. It is usually “adjuvant,” meaning it is used after surgery if a large piece of the tumor remains or if the tumor starts growing back [15][16].

  • Stereotactic Radiosurgery (SRS): A high-dose, single-session treatment used for small, well-defined remnants that are at least 2mm away from the optic nerves [17].
  • Fractionated Radiotherapy (FSRT): Small doses given over several weeks. This is safer for larger tumors or those very close to the vision nerves [17][18].

The Treatment Decision Tree

The path your doctors recommend will likely depend on the results of your surgery and follow-up scans:

Outcome of Surgery Standard Next Step
Gross Total Resection (GTR) Observation: Regular MRIs to monitor for any late recurrence [15].
Subtotal Resection (STR) Wait & Watch or Medical Therapy: Many centers monitor the remnant. Some may use Cabergoline (a pill) to try and stabilize the piece [19][20].
Growing Remnant / Recurrence Radiation or Repeat Surgery: If the piece starts growing toward the vision nerves, radiation is often used to stop it [21][22].

Medical Therapy: The Role of Pills

While there is no “chemotherapy” for NFPAs, some doctors use dopamine agonists like Cabergoline. While it only shrinks the tumor in about 19% of cases, it can help stabilize the tumor and prevent further growth in about 50% of patients with a residual piece [23][19].

Avoiding Substandard Care

Be cautious if a doctor who is not a pituitary specialist recommends:

  • Immediate radiation for a small tumor without discussing a “wait and watch” approach [24].
  • Surgery for a tiny microadenoma that is causing no symptoms and has no threat to vision [3].
  • “Craniotomy” (opening the skull) for a standard NFPA. Nearly all NFPAs should be approached through the nose (transsphenoidal) unless the tumor is exceptionally large or complex [9].

Frequently Asked Questions

When is watchful waiting recommended for a pituitary tumor?
Watchful waiting, or active surveillance, is usually recommended for small tumors that are discovered by accident and are not pressing on your optic nerves or causing any hormone deficiencies. Your doctor will monitor the tumor with regular MRIs to ensure it isn't growing.
Do I need open skull surgery to remove my pituitary tumor?
No, open skull surgery (craniotomy) is rarely used for standard non-functioning pituitary adenomas. Most are safely removed using endoscopic transsphenoidal surgery, where the surgeon uses tiny instruments and a camera to reach the tumor through your nasal passages.
What is a Knosp Grade on my MRI report?
The Knosp Grade measures how much a pituitary tumor has invaded the cavernous sinus, an area containing critical nerves and blood vessels. A high Knosp Grade means the surgeon may need to leave a small piece of the tumor behind to avoid damaging these important structures.
Are there medications or pills to shrink a non-functioning pituitary adenoma?
There is no standard chemotherapy for these tumors. However, some doctors prescribe dopamine agonists like Cabergoline, which is a pill that can help stabilize a leftover tumor piece and prevent further growth in about half of patients.
What happens if surgery cannot remove the entire tumor?
If a piece of the tumor is left behind to protect important nerves or blood vessels, your doctor will likely monitor it with regular MRIs. If this remnant begins to grow toward the vision nerves, radiation therapy is often used to stop the growth.

Questions for Your Doctor

  • • How many endoscopic transsphenoidal surgeries do you perform each year for NFPAs?
  • • Based on my MRI, what is my 'Knosp Grade,' and how likely is a Gross Total Resection (GTR)?
  • • If we find a residual tumor (STR) after surgery, would you recommend immediate radiation or a 'wait and watch' approach with Cabergoline?
  • • Is my tumor close enough to the optic chiasm that surgery is urgent, or can we safely observe it for 6 months?
  • • What is your clinic's rate of postoperative CSF leaks and diabetes insipidus for this procedure?
  • • If we choose radiation, would you recommend Stereotactic Radiosurgery (SRS) or Fractionated Radiotherapy (FSRT) for my specific tumor size?

Questions for You

  • • Does the thought of 'watchful waiting' cause me more anxiety than the thought of surgery?
  • • Have I noticed any subtle changes in my vision, like missing the curb while driving or needing more light to read?
  • • Is it more important to me to have the tumor completely removed (higher risk) or to preserve my current hormone function (lower risk)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Identification of a multidimensional transcriptome signature predicting tumor regrowth of clinically non‑functioning pituitary adenoma.

    Cheng S, Guo J, Zhang Y, et al.

    International journal of oncology 2020; (57(3)):804-812 doi:10.3892/ijo.2020.5087.

    PMID: 32582995
  2. 2

    Chromosomal and oxidative DNA damage in non-functioning pituitary adenomas.

    Bitgen N, Bayram F, Hamurcu Z, et al.

    Endokrynologia Polska 2021; (72(2)):97-103 doi:10.5603/EP.a2020.0084.

    PMID: 33295635
  3. 3

    Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature.

    Rosmino J, Tkatch J, Di Paolo MV, et al.

    Archives of endocrinology and metabolism 2021; (64(5)):614-622.

    PMID: 34033303
  4. 4

    Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas.

    Iglesias P, Arcano K, Triviño V, et al.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017; (49(9)):654-659 doi:10.1055/s-0043-115645.

    PMID: 28759937
  5. 5

    Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects.

    Mercado M, Melgar V, Salame L, Cuenca D

    Endocrinologia, diabetes y nutricion 2017; (64(7)):384-395 doi:10.1016/j.endinu.2017.05.009.

    PMID: 28745610
  6. 6

    The natural history of non-functioning pituitary adenomas: A meta-analysis of conservatively managed tumors.

    Pernik MN, Montgomery EY, Isa S, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; (95()):134-141 doi:10.1016/j.jocn.2021.12.003.

    PMID: 34929637
  7. 7

    Vanishing Pituitary Macroadenoma: A Case Report.

    Sieg EP, Stepanyan H, Payne R, et al.

    Cureus 2016; (8(10)):e838 doi:10.7759/cureus.838.

    PMID: 27900232
  8. 8

    Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery - a prospective study.

    Hantelius V, Ragnarsson O, Johannsson G, et al.

    Pituitary 2024; (27(5)):635-643 doi:10.1007/s11102-024-01401-3.

    PMID: 38767698
  9. 9

    Comparison of Short-Term Outcomes Between Endoscopic and Microscopic Trans-Sphenoidal Surgery for the Treatment of Pituitary Adenoma.

    Li J, Ding W, Huang Z, et al.

    The Journal of craniofacial surgery 2019; (30(8)):2421-2424 doi:10.1097/SCS.0000000000005676.

    PMID: 31261331
  10. 10

    A Meta-Analysis of Endoscopic vs. Microscopic Transsphenoidal Surgery for Non-functioning and Functioning Pituitary Adenomas: Comparisons of Efficacy and Safety.

    Guo S, Wang Z, Kang X, et al.

    Frontiers in neurology 2021; (12()):614382 doi:10.3389/fneur.2021.614382.

    PMID: 33833725
  11. 11

    Comparison of outcomes between endoscopic and microscopic transsphenoidal surgery for the treatment of pituitary adenoma: a meta-analysis.

    Chen X, Huang W, Li H, et al.

    Gland surgery 2020; (9(6)):2162-2174 doi:10.21037/gs-20-851.

    PMID: 33447567
  12. 12

    Radiologic Predictors for Extent of Resection in Pituitary Adenoma Surgery. A Single-Center Study.

    Sanmillán JL, Torres-Diaz A, Sanchez-Fernández JJ, et al.

    World neurosurgery 2017; (108()):436-446 doi:10.1016/j.wneu.2017.09.017.

    PMID: 28899832
  13. 13

    Endoscopic endonasal management of non-functioning pituitary adenomas with cavernous sinus invasion: a 10- year experience.

    Ferreli F, Turri-Zanoni M, Canevari FR, et al.

    Rhinology 2015; (53(4)):308-16 doi:10.4193/Rhino14.309.

    PMID: 26301431
  14. 14

    Predictive factors of postoperative diabetes insipidus in 333 patients undergoing transsphenoidal surgery for non-functioning pituitary adenoma.

    Kinoshita Y, Taguchi A, Tominaga A, et al.

    Pituitary 2022; (25(1)):100-107 doi:10.1007/s11102-021-01175-y.

    PMID: 34283369
  15. 15

    Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma.

    Lee MH, Lee JH, Seol HJ, et al.

    Brain tumor research and treatment 2016; (4(1)):1-7 doi:10.14791/btrt.2016.4.1.1.

    PMID: 27195254
  16. 16

    Tumor Control and Long-Term Survival in Non-Functional Pituitary Adenoma Treated with Adjuvant Radiotherapy. A Retrospective Single Institutional Study.

    Saju AC, Krishnatry R, Goda JS, et al.

    Neurology India 2025; (73(2)):257-263 doi:10.4103/neurol-india.Neurol-India-D-24-00110.

    PMID: 40176214
  17. 17

    Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas.

    Minniti G, Clarke E, Scaringi C, Enrici RM

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2016; (21(4)):370-8 doi:10.1016/j.rpor.2014.09.004.

    PMID: 27330422
  18. 18

    Target delineation and optimal radiosurgical dose for pituitary tumors.

    Minniti G, Osti MF, Niyazi M

    Radiation oncology (London, England) 2016; (11(1)):135 doi:10.1186/s13014-016-0710-y.

    PMID: 27729088
  19. 19

    Management of NFAs: medical treatment.

    Even-Zohar N, Greenman Y

    Pituitary 2018; (21(2)):168-175 doi:10.1007/s11102-018-0865-7.

    PMID: 29344905
  20. 20

    Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.

    Iglesias P, Biagetti B, Araujo-Castro M, et al.

    Journal of neuro-oncology 2022; (160(2)):351-359 doi:10.1007/s11060-022-04149-7.

    PMID: 36355257
  21. 21

    Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas.

    Hefner NA, Cooper O

    Journal of clinical medicine 2025; (14(15)) doi:10.3390/jcm14155203.

    PMID: 40806825
  22. 22

    Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Management of Patients With Residual or Recurrent Nonfunctioning Pituitary Adenomas.

    Sheehan J, Lee CC, Bodach ME, et al.

    Neurosurgery 2016; (79(4)):E539-40 doi:10.1227/NEU.0000000000001385.

    PMID: 27635963
  23. 23

    Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.

    Botelho MS, Franzini ÍA, Nunes-Nogueira VDS, Boguszewski CL

    Pituitary 2022; (25(6)):810-818 doi:10.1007/s11102-022-01257-5.

    PMID: 35902444
  24. 24

    Clinically non-functioning pituitary adenomas.

    Chanson P, Wolf P

    Presse medicale (Paris, France : 1983) 2021; (50(4)):104086 doi:10.1016/j.lpm.2021.104086.

    PMID: 34718111

This page provides educational information about standard treatments for non-functioning pituitary adenomas. Always discuss your specific treatment options and surgical risks with a specialized endocrinologist and neurosurgeon.

Stay up to date

Get notified when new research about Non-functioning pituitary adenoma is published.

No spam. Unsubscribe anytime.